PerkinElmer is a leading provider of prenatal screening for Down syndrome (Trisomy 21), Edward syndrome (Trisomy 18), Patau syndrome (Trisomy 13), Open Neural Tube defects and Pre-eclampsia. We work with healthcare providers globally and assist in implementing programs for safer pregnancies, healthier babies and happier families.
For more than 30 years now, we have been at the forefront of research and development of prenatal screening protocols for risk assessment of Down syndrome, Edward syndrome and Patau syndrome, open neural tube defects and Pre-eclampsia.
PerkinElmer’s evidence and guideline-based screening programs for
aneuploidies and pre-eclampsia risk prediction
combines markers and accredited technology and assays
for high detection rates with low numbers of false positives.
Such screening early in pregnancy allows expectant parents to make timely medical management decisions.
Today, we work closely with hospitals, laboratories, obstetricians and gynecologists, fetal medicine consultants and geneticists the world over, helping monitor pregnancies and facilitating efficient prenatal risk assessment.
Our first and second trimester prenatal screening uses
CE-marked instruments, reagents and assays coupled with state-of-the-art DELFIA® technology
that assures high degree of sensitivity and specificity.
PerkinElmer maternal serum biochemistry assays are based on the robust and sensitive DELFIA® chemistry with measurement by time-resolved fluorometry. The high performance of PerkinElmer DELFIA assays is widely acknowledged, and the assays have been used in numerous key international studies.